Merck's New Launches Must Outrun A Tough Keytruda Comparison After 15% Rally

Merck heads into its third-quarter report with a story that has rarely looked better on paper and a stock that has already started pricing it in. Last quarter management sounded more confident than at any point this year, pointing to a widening roster of launches and pipeline wins arriving ahead of schedule. Now the company has to show that those newer products can carry the load during a quarter that it openly flagged as a difficult comparison for its biggest franchise.

The Street expects earnings of $2.12 per share on revenue of $17.23 billion, essentially flat with the $17.28 billion reported a year ago and well below last year's $2.58 in EPS. That is a contraction quarter on the bottom line, with earnings expected to fall nearly 18% on a top line that barely moves. The Earnings Whisper sits at $2.21, about 4% above consensus, which suggests the informal bar is higher than published estimates. For the full year, management guides to $2.66 to $2.76 in EPS, a figure depressed by a one-time charge of roughly $2.31 per share tied to the Terns acquisition, on revenue of $66.3 billion to $67.3 billion. Consensus of $2.74 sits near the top of the earnings range, while the $66.77 billion revenue estimate lands comfortably in the middle. Analysts, in other words, are already leaning toward the optimistic end on profits.

The central test is Keytruda. Management warned that U.S. growth is moderating as the drug approaches peak penetration in key indications, and that a roughly $250 million wholesaler benefit from the year-ago quarter will not repeat. Add an expected hit to Otovair from unwinding specialty pharmacy purchases, and the quarter starts in a hole. Filling it falls to the growth products that accelerated sharply last quarter. WinRevair has stepped up every quarter, reaching $588 million; Welireg climbed to $271 million and Capvaxive to $184 million. The most telling line may be Keytruda Qlex, the subcutaneous version, which jumped to $463 million from $128 million after securing a permanent billing code in April. Another sizable step up there would validate the argument that Merck can shift patients to a more durable formulation, while a plateau would raise questions about how much of the second-quarter surge was a one-time stocking effect. Early commentary on the Lipvendra oral PCSK9 launch and the Idvinso HIV rollout will also help gauge whether the $70 billion-plus new product opportunity is translating into revenue.

Margins deserve close attention. Gross margin guidance was trimmed to about 81% from 82% on higher inventory reserves, and with earnings expected to fall far faster than revenue, any further slippage would squeeze the cushion between consensus and the top of the guidance range. Investors should also listen for updates on Gardasil, which remained uneven with flat U.S. results, and on pricing policy, given lingering most-favored-nation concerns.

Expectations have clearly warmed. Sentiment improved to 28.9% bullish from 19.2% before the last report, and shares have gained 15.4% since then against a 1.1% rise for the S&P 500. At $148.30 the stock trades well above its 200-day average near $125 but remains about 5% below its post-earnings high of $156.92, so it is not yet testing a breakout. That rally means a merely in-line quarter may not be enough to extend it.

Ultimately, this report hinges on whether the launch portfolio can absorb the Keytruda deceleration without margin erosion. If new products keep compounding and management holds or tightens guidance toward the high end, the improving narrative remains intact. If Qlex stalls or margins slip again, the market may decide the rally ran ahead of the numbers.

This earnings preview was originally published on Earnings Whispers.

This article is for informational purposes only and is not investment advice. Earnings Whispers and its staff may hold positions in the securities mentioned. It was generated automatically, with the help of AI, from Earnings Whispers and company data, and checked by Earnings Whispers before publication.